Evidence map›Paper›PMID 24388423›Full record

ArticleJournal of the American Academy of Dermatology2014

Clinical utility of a circulating tumor cell assay in Merkel cell carcinoma.

Astrid Blom, Shailender Bhatia, Stephanie Pietromonaco, Karen Koehler, Jayasri G Iyer, Kotaro Nagase, Kelly Paulson, Daniel E Sabath, Paul Nghiem

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Academy of Dermatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Merkel Cell Carcinoma Therapeutic Update.Current treatment options in oncology · 2016
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Astrid BlomDepartment of Medicine/Dermatology, University of Washington, Seattle, Washington.
Shailender BhatiaDepartment of Medicine/Oncology, University of Washington, Seattle, Washington.
Stephanie PietromonacoDepartment of Medicine/Dermatology, University of Washington, Seattle, Washington.
Karen KoehlerDepartment of Laboratory Medicine, University of Washington, Seattle, Washington.
Jayasri G IyerDepartment of Medicine/Dermatology, University of Washington, Seattle, Washington.
Kotaro NagaseDepartment of Medicine/Dermatology, University of Washington, Seattle, Washington.
Kelly PaulsonDepartment of Medicine/Dermatology, University of Washington, Seattle, Washington.
Daniel E SabathDepartment of Laboratory Medicine, University of Washington, Seattle, Washington.
Paul NghiemDepartment of Medicine/Dermatology, University of Washington, Seattle, Washington. Electronic address: pnghiem@uw.edu.
University of Washington · US

Funding

University of Washington Medical Scientist Training Program: MD/PhDT32GM007266 · NIGMS · UNIVERSITY OF WASHINGTON · PI HORWITZ, MARSHALL S. · 1985 to 2023
$30.4M
Pathogenetic and prognostic studies for improved therapy of Merkel cell carcinomaK24CA139052 · NCI · UNIVERSITY OF WASHINGTON · PI NGHIEM, PAUL · 2009 to 2018
$1.8M
Humoral and cellular immunity in polyomavirus-linked Merkel cell carcinomaR01CA162522 · NCI · UNIVERSITY OF WASHINGTON · PI NGHIEM, PAUL · 2011 to 2015
$1.6M
Targeting MCPyV to Overcome Immune Evasion in Merkel Cell CarcinomaRC2CA147820 · NCI · UNIVERSITY OF WASHINGTON · PI NGHIEM, PAUL · 2009 to 2010
$1.0M
NCI NIH HHS K24 CA139052NCI NIH HHS K24-CA139052NCI NIH HHS R01 CA162522NCI NIH HHS R01-CA162522-01NCI NIH HHS RC2 CA147820NIGMS NIH HHS T32 GM007266
6 · The paper itself

Abstract

backgroundQuantitation of circulating tumor cells (CTCs) has utility in managing breast, colon, and prostate carcinomas.

objectiveWe sought to determine whether a commercially available CTC assay provides prognostic information in Merkel cell carcinoma (MCC), insight into treatment responses, or both.

methodsWe analyzed CTCs in 52 specimens from 34 patients with MCC.

resultsThe presence of CTCs correlated with extent of disease at blood draw (P = .004). Among 15 patients with regional nodal disease, CTC-negative patients had 80% disease-specific survival at 2 years after the test, versus 29% for CTC-positive patients (P = .015). Among the entire cohort, those without CTCs had 72% MCC-specific survival whereas CTC-positive patients had 25% survival (n = 34, median follow-up 19 months, P = .0003). Fifty seven percent of patients with MCC had a cytokeratin "dot" visible in 20% or more of CTCs, a feature that was absent among CTCs from other carcinomas (0 of 13 cases). LIMITATIONS: CTC assay was performed at variable times after diagnosis and heterogeneity in extent of disease affects interpretability of the data.

conclusionCTC detection in MCC is feasible and appears to add prognostic information, particularly in patients with regional nodal disease. It may also assist clinical management in certain situations, including differentiating metastatic MCC cells from those of other carcinomas.

Indexed as

AdultAgedAged, 80 and overAnalysis of VarianceBiomarkersCarcinoma, Merkel CellDisease-Free SurvivalFemaleHumansImmunohistochemistryKaplan-Meier EstimateKeratinsLongitudinal StudiesMaleMiddle AgedNeoplasm InvasivenessBiomarkersKeratinsbiomarkercirculating tumor cellsdot-like cytokeratinMerkel cell carcinomaneuroendocrine carcinoma of the skinprognosis

Identifiers

PMID24388423
PMCPMC3945022
OpenAlexW1968684048

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.